Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To show what type of criminal scambags these crooks are read the message below I received from spamcop.net. The scammers hacked into spamcops own computer.
2540682044@reports.spamcop.net wrote:
> Email from 132.205.200.145 / Wed, 3 Oct 2007 16:04:27 -0400
>
http://www.spamcop.net/w3m?i=z2540682044zc5324f73a645fc91bd810aee8d3cd2b7z
Thank you for this report, and I apologize that the message you are
reporting originated from a computer system on our network. That
computer has since been located and cleaned up from the compromise that
it suffered. Please do not hesitate to report any further
inappropriate
activity from this, or any other computer on our network.
They can at least use the same prison computer!
A reply from TDA to me re share count-
When a reorganization occurs, such as the reverse split of NWOG, we do not post the changes to accounts until we receive the resulting shares from the transfer agent. This normally occurs within 1 - 5 business days of the date of the action. However, there have been instances when this has taken longer with the OTCBB stocks. As soon as we receive the resulting shares, your account will be updated. Best regards, xxxxxx S.Apex Client Services, TD AMERITRADEDivision of TD AMERITRADE, Inc.
mthead, I for one appreciated your DD way back then and posted it (post was probably removed as one where I said I was tired of those blaming NSS for stock pps). I am one who looks at both pro or con posts vs those who buy in and "by gosh I bought and it is 100% pure"! Wonder why many of those posters are so quiet now?
NWOG Inc. Will Publish Reports on Reserves During the Month of October
9:14a ET October 5, 2007 (Market Wire)
North-West Oil Group Inc. (PINKSHEETS: NWOL) today announced that the management of the company North-West Oil Group Inc. will publish Findings to the reports about valuation of the market value of 100% shares of OOO "North-West Oil Group-Saratov" and OOO "Company "Neftegazenergo" in the course of next two weeks.
About North West Oil Group Inc. (formerly Nord Oil International): North West Oil Group Inc. is a publicly traded Oil & Gas company trading under the ticker symbol NWOL.PK on the U.S. Pinksheets market.
Forward-Looking Statements
All statements in this news release other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
Contact: Tatiana Sazonova North-West Oil Group Inc. Tel: +7 495 621 11 15 E-Mail: sazonova@szng.ru Web: http://www.szng.ru
SOURCE: North-West Oil Group
mailto:sazonova@szng.ru http://www.szng.ru
According to the pumpers it is :)
No wrath here, I have observed the same thing. A few months ago I posted on RB and "suggested" there was another board for posters to look at. I like IH because of the ability to save posts without having to print important info as you do at RB.
Thanks for chart otc and good luck. We have a couple more folks looking at board according to boardmarks. The co has not done a very good job of getting word out imo.
In ref to last two posts and biophos problems here is a post taken from another board:
By: joecris_us
04 Oct 2007, 07:28 PM EDT
Msg. 14244 of 14244
(This msg. is a reply to 14243 by prefab1.)
Jump to msg. #
If that's the case and it is ever proven that they were writing scripts knowing the negative side effects, I hope they have plenty of malpractice insurance.Upshaw Smith has made changes in the marketing of Fortical,according to Mr. Levy, to go after the Fosamax and Boniva market.If they have the success any where near the success of the initial rool out of fortical they should report excellant earnings.
Or this report from 2006-and MD's do not have a clue as of today!
Vioxx Study Indicates Risk Occurs Early, Lasts Long
19 May, 2006 19:51 GMT
Unpublished data from the Merck & Co. study that led the drugmaker to halt sales of Vioxx appear to show the blockbuster painkiller raised the risk of heart attack and stroke within just a few months -- not after at least 18 months' use, as Merck has consistently argued.
The company disputed that Thursday, saying it is "not scientifically appropriate" to draw conclusions based on a key graph in a 108-page report on the data.
The news, first reported by National Public Radio, comes after prominent doctors said Merck misrepresented other data from the same study late last Thursday.
No 18-Month Delay
Merck officials said last week that data, from a follow-up of patients a year after they stopped taking Vioxx, showed heart and stroke risk ended soon after patients stopped taking it -- and that patients who later had such complications didn't have a legitimate lawsuit. But several doctors told The Associated Press they believe the data instead shows the heart and stroke risks persisted for at least a year.
The newly public data show the increased cardiovascular risk with Vioxx use likely begins as early as four to six months and then gets bigger, said Dr. Steven Nissen, a Cleveland Clinic cardiologist who heads a huge international study of painkiller safety.
"It didn't really make a lot of sense that nothing happened for 18 months and then all of a sudden you would see a hazard," Nissen said Thursday.
Other doctors concurred.
Because few heart attacks and strokes occurred, Nissen said scientists cannot definitively say the painkiller caused the excess complications in the Vioxx group compared to those in the placebo group, but most would interpret it that way.
"There's no 18-month delay until you see harm," said Dr. Curt Furberg, professor of public health science at Wake Forest University School of Medicine.
"This has implications for patients and all the legal cases that are under way," he said, adding, "You're probably at risk the rest of your life."
Complications Excluded?
The study, known by the acronym APPROVe, included 2,586 patients, with half taking Vioxx and half dummy pills for three years. Patients were enrolled in the study from February 2000 to November 2001.
By September 2004, Merck said, the Vioxx group had about twice as many heart attacks and strokes, leading the Whitehouse Station, New Jersey-based company to pull the drug from the market then. As lawsuits over Vioxx have topped the 11,500 mark, Merck has insisted there was no increased risk until 18 months -- a key argument in its legal strategy.
"The new APPROVe data do not establish that the risk for Vioxx starts earlier than had been previously reported," Merck repeated Thursday in a statement. Merck declined to provide a company official to answer questions on the record.
When the company first published APPROVe data, in February 2005 in the New England Journal of Medicine, it only included complications patients had within 14 days of stopping the drug, even if they stopped early. A key graph in that report didn't show higher risk until after 18 months.
The lead author of that report, Dr. Robert Bresalier of M.D. Anderson Cancer Center, told The Associated Press he is still reviewing the new data but doesn't think the data show that Vioxx risk began earlier. He said the original and new graphs look about the same.
Still, that's not the proper way to report studies, said Dr. Alastair Wood, professor of pharmacology at Vanderbilt University. He said that method would exclude complications suffered by patients who stopped taking Vioxx early because of side effects such as rising blood pressure, then had a heart attack more than two weeks later.
If Merck knowingly excluded those complications, he said, "that's outrageous."
60 Percent Higher Heart Attack, Stroke Risk
The complete data follow about 85 percent of patients throughout the full study, producing a different picture.
A key graph and two related tables in the 108-page report, which Merck supplied to The Associated Press, seem to indicate that within three or four months, a higher risk of heart complications began for patients on Vioxx. The tables show that over the first six months, the Vioxx group had about a 60 percent higher chance of having a heart attack or stroke.
The risk to the Vioxx group bounces around over the following months, as is common in clinical studies with small numbers of complications, then rises after 18 months' use.
Merck has submitted the report to the Food and Drug Administration, which has said it is reviewing the new data. A spokeswoman did not return messages Thursday.
Of the six Vioxx lawsuits that have reached verdicts, Merck has lost three.
If you are holding osteo drug stocks or know someone taking them, you might want to check this link out:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=23425654
If you are taking, or know someone, on osteo drugs then read this:
http://www.askapatient.com/viewrating.asp?drug=20560&name=FOSAMAX
Run along to the AURC board blackie, they're talking nice about you over there :).
By the way, I'm still waiting on my .19 AURC pps you promised within a week---two months ago not to say the .14 you promised last week!
Looks like the feds finally did something about the email criminals. FYI-you can send your spam emails to spamcop.net and they will take down the link. The govt folks at spam@uce.gov have done little or nothing from what I see.
Feds crack down on international e-mail scams
By RANDOLPH E. SCHMID
Associated Press Writer
Published on: 10/03/07
WASHINGTON (AP) — The e-mails arrive out of the blue, from Nigeria or other exotic countries. They tell of inheritances, political problems, other reasons someone needs to get money out of the country. If you help, they promise to let you share the money.
Unfortunately, thousands of people fall for the scam, losing an average of $3,000 to $4,000 each.
So far this year, an average of more than 800 people a month have filed complaints about such scams.
Hoping to stem the losses, the U.S. Postal Inspection Service announced an international crackdown Wednesday in which more than 540,000 fake checks with a face value of $2.1 billion have been seized.
There have been 60 arrests in the Netherlands, 16 in Nigeria and one in Canada, the Postal Inspection Service said, and the effort is continuing.
"There is no room in the mail for any of these phony come-ons," Postmaster General John Potter said.
Most of the cons start with e-mails telling of an inheritance or lottery win and ask the victim to help bring the money to the United States. The victim is asked to cash a check that comes in the mail and to send part of the money back to the person sending it, said Greg Campbell, inspector in charge of global security and investigations for the Postal Inspection Service.
Then that person disappears with the money and the original check bounces, leaving the victim with a loss.
Retired people have lost their nest eggs and young families have been defrauded of their savings for a home, Potter said.
Many of the cases originate in the Netherlands, where West African con artists operate from Internet cafes, said Johan Van Hartskamp, commissioner of the Amsterdam police.
In what he called "Operation Dutch Treat," police have arrested 60 people there, with three extradited to the United States and four more facing extradition. The rest are being prosecuted in the Netherlands, he said.
Ibrahim Lamorde, director of the Nigerian Economic and Financial Crimes Commission, said the problem is monumental and "will only be surmounted through global efforts."
U.S. Assistant Attorney General Alice Fisher said: "There is no lottery. There is no inheritance. The checks are not real. But there are real victims. The crime knows no borders, and our coordinated law enforcement knows no borders."
—
On the Net:
Postal Anti-Fraud: http://www.fakechecks.org
I hope they arrested some stock scammers also.
Feds crack down on international e-mail scams
By RANDOLPH E. SCHMID
Associated Press Writer
Published on: 10/03/07
WASHINGTON (AP) — The e-mails arrive out of the blue, from Nigeria or other exotic countries. They tell of inheritances, political problems, other reasons someone needs to get money out of the country. If you help, they promise to let you share the money.
Unfortunately, thousands of people fall for the scam, losing an average of $3,000 to $4,000 each.
So far this year, an average of more than 800 people a month have filed complaints about such scams.
Hoping to stem the losses, the U.S. Postal Inspection Service announced an international crackdown Wednesday in which more than 540,000 fake checks with a face value of $2.1 billion have been seized.
There have been 60 arrests in the Netherlands, 16 in Nigeria and one in Canada, the Postal Inspection Service said, and the effort is continuing.
"There is no room in the mail for any of these phony come-ons," Postmaster General John Potter said.
Most of the cons start with e-mails telling of an inheritance or lottery win and ask the victim to help bring the money to the United States. The victim is asked to cash a check that comes in the mail and to send part of the money back to the person sending it, said Greg Campbell, inspector in charge of global security and investigations for the Postal Inspection Service.
Then that person disappears with the money and the original check bounces, leaving the victim with a loss.
Retired people have lost their nest eggs and young families have been defrauded of their savings for a home, Potter said.
Many of the cases originate in the Netherlands, where West African con artists operate from Internet cafes, said Johan Van Hartskamp, commissioner of the Amsterdam police.
In what he called "Operation Dutch Treat," police have arrested 60 people there, with three extradited to the United States and four more facing extradition. The rest are being prosecuted in the Netherlands, he said.
Ibrahim Lamorde, director of the Nigerian Economic and Financial Crimes Commission, said the problem is monumental and "will only be surmounted through global efforts."
U.S. Assistant Attorney General Alice Fisher said: "There is no lottery. There is no inheritance. The checks are not real. But there are real victims. The crime knows no borders, and our coordinated law enforcement knows no borders."
—
On the Net:
Postal Anti-Fraud: http://www.fakechecks.org
UPDATE 2-U.S. reviews osteoporosis drugs' effect on heart
Mon Oct 1, 2007 6:30pm EDT
(Recasts paragraphs 1-2, adds Merck comments, context on atrial fibrillation)
By Lisa Richwine and Kim Dixon
WASHINGTON, Oct 1 (Reuters) - U.S. regulators said on Monday they were reviewing whether certain osteoporosis drugs, including those made by Merck Inc (MRK.N: Quote, Profile, Research) and Novartis AG (NOVN.VX: Quote, Profile, Research), may be linked to a dangerously fast heartbeat.
The U.S. Food and Drug Administration said it would study the class of osteoporosis drugs known as bisphosphonates after two reports in the New England Journal of Medicine finding increased rates of serious atrial fibrillation (AF), a type of abnormal heartbeat, in patients who took either Merck's Fosamax or Novartis' Reclast.
"Upon initial review, it is unclear how these data on serious atrial fibrillation should be interpreted. Therefore, FDA does not believe that healthcare providers or patients should change either their prescribing practices or their use of bisphosphonates at this time," the FDA said in a statement.
Osteoporosis weakens bones and increases the risk of fractures.
Atrial fibrillation puts patients at risk for blood clots, which can cause strokes. AF is common in people over age 65, the population studied in the New England Journal article, the FDA said.
The article described increased rates of serious AF that were life-threatening, resulting in hospitalization or disability, the FDA said.
The FDA alert is part of a broader effort to notify the public earlier in the process when the agency reviews potential safety problems in drugs. It follows intense criticism of the FDA after Merck's painkiller Vioxx was pulled from the market in 2004 for links to heart attacks.
The FDA said it was seeking additional data for an in-depth review of the issue with the entire class of drugs. The review may take up to 12 months, the agency said.
A spokesman for Merck referred to a statement issued by the company when the New England Journal of Medicine study appeared in May. The drugmaker noted then that the link between Fosamax and serious AF was not statistically different than with a placebo, although it was numerically higher.
A Novartis spokesperson was not available for comment.
Bisphosphonates are used primarily to increase bone mass and reduce the risk of fractures in patients with osteoporosis. They also are used to slow bone turnover in patients with a disorder called Paget's disease and to treat bone metastases and lower blood calcium in cancer patients.
The other U.S.-approved bisphosphonates are Roche Holding AG (ROG.VX: Quote, Profile, Research) and GlaxoSmithKline PLC's (GSK.L: Quote, Profile, Research) Boniva; Actonel, sold by Procter & Gamble (PG.N: Quote, Profile, Research) and Sanofi-Aventis (SASY.PA: Quote, Profile, Research); Novartis AG's Zometa and Aredia; P&G's Didronel, and Sanofi's Skelid.
P&G spokeswoman Paula Koenigs said the company has reviewed its data and that "the data for Actonel don't suggest a safety concern."
Representatives of other companies that make bisphosphonates were not available for comment.
© Reuters 2006. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Reuters journalists are subject to the Reuters Editorial Handbook which requires fair presentation and disclosure of relevant interests
North West Oil Group Inc. Commences Drilling in Saratov Region
9:24a ET October 4, 2007 (Market Wire)
North-West Oil Group Inc. (PINKSHEETS: NWOL) today announced that it has commenced the drilling of the first of two potentially commercial wells in the licensed and producing oil fields located in Saratov Region. http://www.szng.ru/sar_11.html
Published reports indicate the Saratov Region has significant reserves of natural resources, including large deposits of natural gas, oil shale, salt, chalk, limestone, clay, sand, dolomites, and aragonite. The oil shale deposits alone equal to over a billion tons. Oil and gas are considered to be the most significant natural assets of the region. The oil and gas production has been developed since 1944. In total, oil deposits of the region are estimated at 500 million MT, 43.1% of which are extractable. Projected reserves of gas condensate are 164 million MT, 56.2% of which are extractable.
Mr. Malyshev, President of North West Oil Group Inc. (PINKSHEETS: NWOL), stated, "We've now successfully taken the pro-active steps to reorganize our capital structure more commensurate with the company we intend to be. Although we continue to systematically address and resolve past legacy issues, we continue to remain focused on the many potentially exciting opportunities ahead of us. Today's announcement of spudding this new well is one of those opportunities that we believe has the potential to further enhance cash flow and profitability."
About North West Oil Group Inc. (formerly Nord Oil International): North West Oil Group Inc. is a publicly traded Oil & Gas company trading under the ticker symbol NWOL.PK on the U.S. Pinksheets market.
Forward-Looking Statements
North West Oil Group Inc. Commences Drilling in Saratov Region
9:24a ET October 4, 2007 (Market Wire)
North-West Oil Group Inc. (PINKSHEETS: NWOL) today announced that it has commenced the drilling of the first of two potentially commercial wells in the licensed and producing oil fields located in Saratov Region. http://www.szng.ru/sar_11.html
Published reports indicate the Saratov Region has significant reserves of natural resources, including large deposits of natural gas, oil shale, salt, chalk, limestone, clay, sand, dolomites, and aragonite. The oil shale deposits alone equal to over a billion tons. Oil and gas are considered to be the most significant natural assets of the region. The oil and gas production has been developed since 1944. In total, oil deposits of the region are estimated at 500 million MT, 43.1% of which are extractable. Projected reserves of gas condensate are 164 million MT, 56.2% of which are extractable.
Mr. Malyshev, President of North West Oil Group Inc. (PINKSHEETS: NWOL), stated, "We've now successfully taken the pro-active steps to reorganize our capital structure more commensurate with the company we intend to be. Although we continue to systematically address and resolve past legacy issues, we continue to remain focused on the many potentially exciting opportunities ahead of us. Today's announcement of spudding this new well is one of those opportunities that we believe has the potential to further enhance cash flow and profitability."
About North West Oil Group Inc. (formerly Nord Oil International): North West Oil Group Inc. is a publicly traded Oil & Gas company trading under the ticker symbol NWOL.PK on the U.S. Pinksheets market.
Forward-Looking Statements
Good post fraud. Lets see how much lipstick the Kool-Aid drinking pumpers put on this,lol.
Uh, did I say that? I was referring to Cato the clock" who I have on igg.
First Patient Enrolled in Phase II Cancer Trial
Wednesday October 3, 6:00 am ET
YONKERS, N.Y.--(BUSINESS WIRE)--A new Phase II open label study at McGill University will explore the effect of an investigational drug on patients with recurrent or advanced cancer. Researchers indicate the treatment may help patients who suffer from severe appetite loss, fatigue and weight loss when undergoing aggressive cancer therapy.
ADVERTISEMENT
Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, today announced the enrollment of the first patient into the Phase II clinical trial.
The trial is being conducted at McGill University Health Centre (MUHC) in Montreal, Quebec. Dr. Martin Chasen, a medical oncologist / palliative care physician and Clinical Director of the McGill Cancer Nutrition and Rehabilitation Program at McGill University, is the Principal Investigator.
The Phase II open label study will examine the effect of a 4.0 mL subcutaneous dose of AVR118 on weight, appetite, performance status, and other measures of quality of life in patients with recurrent or advanced malignancies. AVR118 will be administered daily for a trial period of 28 days. Patients who appear to benefit from the trial period dosing will be eligible to continue on AVR118, generating longer term efficacy data.
According to Dr. Chasen, "AVR118 may offer a new treatment paradigm in palliative care. Early identification and treatment of patients will hopefully enable us to reduce the severely debilitating effects of cachexia and chemotherapy."
Enrollment initially will include 14 patients between the ages of 18 and 85 who have recurrent or advanced malignancies and are suffering from symptoms of cachexia, including muscle wasting, severe fatigue and loss of appetite. Pending review of preliminary data, there is a provision to increase enrollment to 30 patients.
"We are excited to have our first patient enrolled at McGill and hope to improve the quality of life for all patients in this trial. Our company remains committed to contributing to cancer symptom control and advancing palliative care research," said Stephen M. Elliston, President and Chief Executive Officer of ADVR.
Advanced Viral Research Corp. is a New York biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the control of symptoms associated with cancer and other serious diseases. Its initial compound AVR118 represents a new class of cytoprotective agent that targets, among other things, cachexia related disorders. Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy. AVR118 has also been shown to have topical wound healing properties in animal models.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
For further information regarding Advanced Viral Research Corp., please visit the website at http://www.adviral.com.
Contact:
The Signature Agency
Gayle Challinor, 800-870-8700 or 919-878-8989
or
Advanced Viral Research Corp.
Stephen M. Elliston, 914-376-7383
Fax: 919-878-3939
--------------------------------------------------------------------------------
Source: Advanced Viral Research
First Patient Enrolled in Phase II Cancer Trial
Wednesday October 3, 6:00 am ET
YONKERS, N.Y.--(BUSINESS WIRE)--A new Phase II open label study at McGill University will explore the effect of an investigational drug on patients with recurrent or advanced cancer. Researchers indicate the treatment may help patients who suffer from severe appetite loss, fatigue and weight loss when undergoing aggressive cancer therapy.
ADVERTISEMENT
Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, today announced the enrollment of the first patient into the Phase II clinical trial.
The trial is being conducted at McGill University Health Centre (MUHC) in Montreal, Quebec. Dr. Martin Chasen, a medical oncologist / palliative care physician and Clinical Director of the McGill Cancer Nutrition and Rehabilitation Program at McGill University, is the Principal Investigator.
The Phase II open label study will examine the effect of a 4.0 mL subcutaneous dose of AVR118 on weight, appetite, performance status, and other measures of quality of life in patients with recurrent or advanced malignancies. AVR118 will be administered daily for a trial period of 28 days. Patients who appear to benefit from the trial period dosing will be eligible to continue on AVR118, generating longer term efficacy data.
According to Dr. Chasen, "AVR118 may offer a new treatment paradigm in palliative care. Early identification and treatment of patients will hopefully enable us to reduce the severely debilitating effects of cachexia and chemotherapy."
Enrollment initially will include 14 patients between the ages of 18 and 85 who have recurrent or advanced malignancies and are suffering from symptoms of cachexia, including muscle wasting, severe fatigue and loss of appetite. Pending review of preliminary data, there is a provision to increase enrollment to 30 patients.
"We are excited to have our first patient enrolled at McGill and hope to improve the quality of life for all patients in this trial. Our company remains committed to contributing to cancer symptom control and advancing palliative care research," said Stephen M. Elliston, President and Chief Executive Officer of ADVR.
Advanced Viral Research Corp. is a New York biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the control of symptoms associated with cancer and other serious diseases. Its initial compound AVR118 represents a new class of cytoprotective agent that targets, among other things, cachexia related disorders. Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy. AVR118 has also been shown to have topical wound healing properties in animal models.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
For further information regarding Advanced Viral Research Corp., please visit the website at http://www.adviral.com.
Contact:
The Signature Agency
Gayle Challinor, 800-870-8700 or 919-878-8989
or
Advanced Viral Research Corp.
Stephen M. Elliston, 914-376-7383
Fax: 919-878-3939
--------------------------------------------------------------------------------
Source: Advanced Viral Research
NanoViricides Treatments Proven Superior in Testing; Results Released at International Conference
http://feeds.mn1.com/nanoviricides_treatments_proven_superior_in_testing_results.htm
posted Wednesday, 3 October 2007
MN1 Staff Writer
WEST HAVEN, Conn. (October 3, 2007) - NanoViricides Inc. (OTCBB: NNVC) recently presented important results regarding the company's FluCide-I and FluCide-HP treatments for influenzas.
Dr. Eugene Seymour, MD, MPH, CEO of the company commented at the 5th International Bird Flu Conference in Las Vegas: "In our completely lethal mouse model, efficacy of FluCide-I has improved significantly, and even FluCide-HP, which is designed against high path influenzas, showed very strong efficacy against H1N1, which was the cause of 1918 Spanish Flu pandemic."
NanoViricides is on the cutting edge of the battle against these influenzas, and representatives from Vietnam, Indonesia, and Turkey have made it clear to the company that no good treatment options exist currently.
Seymour relayed their sentiments in his presentation at the conference: "These speakers complained that patients sought medical care too late for Tamiflu - the drug currently recommended by the World Health Organization - to be effective. They also pointed out that resistance to Tamiflu develops quickly. Vaccines may be ineffective in the field due to the antigenic drift caused by the observed rapid mutation rate of the influenza virus, according to these physicians. They fear that antibodies alone also will be ineffective as drugs in the field due to the antigenic drift."
Included in the company's research results were findings that the improved FluCide-I is now 16X (1,600 percent) better than oseltamivir (active ingredient of TamiFlu), and FluCide-HP is 8X (800 percent) better than oseltamivir, based on dose-response comparisons.
NanoViricides is a development stage company that is creating special purpose nanomaterials for viral therapy. The company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.
The company is also working on nanoviricides against Dengue viruses with the Walter Reed Army Institute of Research. Dengue virus is currently causing the worst outbreak in several years in Latin America, and has already crossed the border into the U.S.
NanoViricides is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, among others.
NanoViricides Treatments Proven Superior in Testing; Results Released at International Conference
http://feeds.mn1.com/nanoviricides_treatments_proven_superior_in_testing_results.htm
posted Wednesday, 3 October 2007
MN1 Staff Writer
WEST HAVEN, Conn. (October 3, 2007) - NanoViricides Inc. (OTCBB: NNVC) recently presented important results regarding the company's FluCide-I and FluCide-HP treatments for influenzas.
Dr. Eugene Seymour, MD, MPH, CEO of the company commented at the 5th International Bird Flu Conference in Las Vegas: "In our completely lethal mouse model, efficacy of FluCide-I has improved significantly, and even FluCide-HP, which is designed against high path influenzas, showed very strong efficacy against H1N1, which was the cause of 1918 Spanish Flu pandemic."
NanoViricides is on the cutting edge of the battle against these influenzas, and representatives from Vietnam, Indonesia, and Turkey have made it clear to the company that no good treatment options exist currently.
Seymour relayed their sentiments in his presentation at the conference: "These speakers complained that patients sought medical care too late for Tamiflu - the drug currently recommended by the World Health Organization - to be effective. They also pointed out that resistance to Tamiflu develops quickly. Vaccines may be ineffective in the field due to the antigenic drift caused by the observed rapid mutation rate of the influenza virus, according to these physicians. They fear that antibodies alone also will be ineffective as drugs in the field due to the antigenic drift."
Included in the company's research results were findings that the improved FluCide-I is now 16X (1,600 percent) better than oseltamivir (active ingredient of TamiFlu), and FluCide-HP is 8X (800 percent) better than oseltamivir, based on dose-response comparisons.
NanoViricides is a development stage company that is creating special purpose nanomaterials for viral therapy. The company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.
The company is also working on nanoviricides against Dengue viruses with the Walter Reed Army Institute of Research. Dengue virus is currently causing the worst outbreak in several years in Latin America, and has already crossed the border into the U.S.
NanoViricides is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, among others.
Is the human clock still working this board?
Names please.
PainCare Reports on Key Corporate Developments
12:41p ET October 3, 2007 (PR NewsWire)
Randy Lubinsky, CEO of PainCare Holdings, Inc. (Amex: PRZ), one of the nation's leading providers of pain-focused medical and surgical solutions and services, today issued the following corporate update detailing recent developments that are expected to positively impact and support the Company's refined long term growth strategy. Specifically, Lubinsky stated:
"We have succeeded in implementing a series of important restructuring initiatives that have now positioned us to direct our focus on the ongoing recovery and planned revitalization of PainCare. Central to our corporate restructuring plan, PainCare completed the divestitures of its Ambulatory Surgery Centers (ASCs) located in Maryland and South Florida, generating more than $29 million in cash and debt relief and providing for $2.3 million in potential earn-out provisions over the next couple of years. Moreover, as a consequence of selling the ASCs, we succeeded in reducing our outstanding debt obligations to our senior lender from $30 million to $8.5 million, thus materially strengthening our balance sheet. Further, we remain in active discussions with our senior lender to resolve the remaining debt balance, and recently received a six-month forbearance on the associated note. Details related to this forbearance agreement, may be found in a Form 8-K that will be filed with the SEC in the next several days.
"In tandem with the sale of our ASCs, PainCare also initiated an in-depth review of our Practice Management Group. This evaluation process resulted in our election to either close or sell back to the original shareholder physician 10 of the 20 practices that comprised our former national network. The collective impact of this restructuring of our network of affiliated practices should yield PainCare a much stronger operating platform in 2008 and beyond. Although we may yet divest two more practices, which will be determined prior to year end, we plan to distinguish all remaining practices as nationally recognized Centers of Excellence for the delivery of state-of- the-art pain care and treatment.
"We have also been working to support those business interests that, on a moving forward basis, will serve as true driving forces behind PainCare's revitalization efforts.
"These include Caperian, Inc., a wholly-owned subsidiary of PainCare, whose mission is to create and drive value through development of commercial medical real estate projects on a national basis, including surgery centers, medical buildings and specialty hospitals and clinics.
"Integrated Pain Solutions (IPS), another wholly-owned subsidiary, has been gaining considerable traction in its effort to emerge as the nation's first managed services organization solely dedicated to improving care and reducing costs associated with the treatment of pain. Since first launching operations in early 2007, IPS has made progress in ramping up its infrastructure and beginning the transformation from a development stage to a revenue generating company. To date, IPS has established provider networks in Colorado, Florida, Illinois, Michigan, New Jersey and Tennessee (with plans to expand into Alabama, California, Georgia, New York, Ohio, Pennsylvania and Texas over the next six to nine months), and has begun implementation of its contract with Coalition America, the nation's leader in medical claim savings.
"In addition to directing growth in our Practice Management Group, Caperian and IPS, PainCare is also exploring opportunities to leverage our national reputation and medical marketing expertise to promote the creation of additional revenue channels for our Company.
"In closing, it is our greatest hope that the recovery underway at PainCare will help to ultimately revitalize shareholder confidence in our Company. PainCare's longstanding investors, Midsummer Capital and Islandia, increased its investment in our Company by way of a $2 million equity placement, helping to provide cash resources needed to support our operations. Specific terms and conditions of this equity transaction, which closed on Tuesday of this week and involved the issuance of both common shares and warrants, will be detailed in a related Form 8-K to be filed with the SEC in the next several days.
"To those shareholders who have stood by us through the many challenges we've endured and overcome over the past two years, I'd like to once again extend my thanks for your ongoing support," concluded Lubinsky.
About PainCare Holdings, Inc.
Headquartered in Orlando, Florida, PainCare Holdings, Inc. is one of the nation's leading providers of pain-focused medical and surgical solutions and services. Through its proprietary network of acquired or managed physician practices, and in partnership with independent physician practices and medical institutions throughout the United States and Canada, PainCare is committed to utilizing the most advanced science and technologies to diagnose and treat pain stemming from neurological and musculoskeletal conditions and disorders.
Through its wholly owned subsidiary, Caperian, Inc., PainCare offers medical real estate and development services. Through Integrated Pain Solutions, the Company is engaged in pioneering the nation's first managed services organization that offers a multi-disciplinary healthcare network focused on the treatment of pain. For more information on PainCare Holdings, please visit www.paincareholdings.com.
This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are made based on management's current expectations or beliefs as well as assumptions made by, and information currently available to, management. These forward-looking statements, which may include statements regarding our future financial performance or results of operations, including expected revenue growth, cash flow growth, future expenses, future operating margins and other future or expected performance, are subject to the following risks: the acquisition of businesses or the launch of new lines of business, which could increase operating expenses and dilute operating margins; the inability to attract new patients by our owned practices, the managed practices and the limited management practice; increased competition, which could lead to negative pressure on our pricing and the need for increased marketing; the inability to maintain, establish or renew relationships with physician practices, whether due to competition or other factors; the inability to comply with regulatory requirements governing our owned practices, the managed practices and the limited management practices; that projected operating efficiencies will not be achieved due to implementation difficulties or contractual spending commitments that cannot be reduced; and to the general risks associated with our businesses.
In addition to the risks and uncertainties discussed above you can find additional information concerning risks and uncertainties that would cause actual results to differ materially from those projected or suggested in the forward-looking statements in the reports that we have filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release represent our judgment as of the date of this release and you should not unduly rely on such statements. Unless otherwise required by law, we undertake no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise after the date of this press release. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in the filing may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.
For more information, please contact: Media Relations Suzanne Beranek, APR, Beranek Communications, LLC 407-475-0763 or via email at suzanne@beranekcommunications.com Investor/Shareholder Relations Elite Financial Communications Group, LLC Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist 407-585-1080 or via email at prz@efcg.net
SOURCE PainCare Holdings, Inc.
http://www.paincareholdings.com
PainCare Reports on Key Corporate Developments
12:41p ET October 3, 2007 (PR NewsWire)
Randy Lubinsky, CEO of PainCare Holdings, Inc. (Amex: PRZ), one of the nation's leading providers of pain-focused medical and surgical solutions and services, today issued the following corporate update detailing recent developments that are expected to positively impact and support the Company's refined long term growth strategy. Specifically, Lubinsky stated:
"We have succeeded in implementing a series of important restructuring initiatives that have now positioned us to direct our focus on the ongoing recovery and planned revitalization of PainCare. Central to our corporate restructuring plan, PainCare completed the divestitures of its Ambulatory Surgery Centers (ASCs) located in Maryland and South Florida, generating more than $29 million in cash and debt relief and providing for $2.3 million in potential earn-out provisions over the next couple of years. Moreover, as a consequence of selling the ASCs, we succeeded in reducing our outstanding debt obligations to our senior lender from $30 million to $8.5 million, thus materially strengthening our balance sheet. Further, we remain in active discussions with our senior lender to resolve the remaining debt balance, and recently received a six-month forbearance on the associated note. Details related to this forbearance agreement, may be found in a Form 8-K that will be filed with the SEC in the next several days.
"In tandem with the sale of our ASCs, PainCare also initiated an in-depth review of our Practice Management Group. This evaluation process resulted in our election to either close or sell back to the original shareholder physician 10 of the 20 practices that comprised our former national network. The collective impact of this restructuring of our network of affiliated practices should yield PainCare a much stronger operating platform in 2008 and beyond. Although we may yet divest two more practices, which will be determined prior to year end, we plan to distinguish all remaining practices as nationally recognized Centers of Excellence for the delivery of state-of- the-art pain care and treatment.
"We have also been working to support those business interests that, on a moving forward basis, will serve as true driving forces behind PainCare's revitalization efforts.
"These include Caperian, Inc., a wholly-owned subsidiary of PainCare, whose mission is to create and drive value through development of commercial medical real estate projects on a national basis, including surgery centers, medical buildings and specialty hospitals and clinics.
"Integrated Pain Solutions (IPS), another wholly-owned subsidiary, has been gaining considerable traction in its effort to emerge as the nation's first managed services organization solely dedicated to improving care and reducing costs associated with the treatment of pain. Since first launching operations in early 2007, IPS has made progress in ramping up its infrastructure and beginning the transformation from a development stage to a revenue generating company. To date, IPS has established provider networks in Colorado, Florida, Illinois, Michigan, New Jersey and Tennessee (with plans to expand into Alabama, California, Georgia, New York, Ohio, Pennsylvania and Texas over the next six to nine months), and has begun implementation of its contract with Coalition America, the nation's leader in medical claim savings.
"In addition to directing growth in our Practice Management Group, Caperian and IPS, PainCare is also exploring opportunities to leverage our national reputation and medical marketing expertise to promote the creation of additional revenue channels for our Company.
"In closing, it is our greatest hope that the recovery underway at PainCare will help to ultimately revitalize shareholder confidence in our Company. PainCare's longstanding investors, Midsummer Capital and Islandia, increased its investment in our Company by way of a $2 million equity placement, helping to provide cash resources needed to support our operations. Specific terms and conditions of this equity transaction, which closed on Tuesday of this week and involved the issuance of both common shares and warrants, will be detailed in a related Form 8-K to be filed with the SEC in the next several days.
"To those shareholders who have stood by us through the many challenges we've endured and overcome over the past two years, I'd like to once again extend my thanks for your ongoing support," concluded Lubinsky.
About PainCare Holdings, Inc.
Headquartered in Orlando, Florida, PainCare Holdings, Inc. is one of the nation's leading providers of pain-focused medical and surgical solutions and services. Through its proprietary network of acquired or managed physician practices, and in partnership with independent physician practices and medical institutions throughout the United States and Canada, PainCare is committed to utilizing the most advanced science and technologies to diagnose and treat pain stemming from neurological and musculoskeletal conditions and disorders.
Through its wholly owned subsidiary, Caperian, Inc., PainCare offers medical real estate and development services. Through Integrated Pain Solutions, the Company is engaged in pioneering the nation's first managed services organization that offers a multi-disciplinary healthcare network focused on the treatment of pain. For more information on PainCare Holdings, please visit www.paincareholdings.com.
This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are made based on management's current expectations or beliefs as well as assumptions made by, and information currently available to, management. These forward-looking statements, which may include statements regarding our future financial performance or results of operations, including expected revenue growth, cash flow growth, future expenses, future operating margins and other future or expected performance, are subject to the following risks: the acquisition of businesses or the launch of new lines of business, which could increase operating expenses and dilute operating margins; the inability to attract new patients by our owned practices, the managed practices and the limited management practice; increased competition, which could lead to negative pressure on our pricing and the need for increased marketing; the inability to maintain, establish or renew relationships with physician practices, whether due to competition or other factors; the inability to comply with regulatory requirements governing our owned practices, the managed practices and the limited management practices; that projected operating efficiencies will not be achieved due to implementation difficulties or contractual spending commitments that cannot be reduced; and to the general risks associated with our businesses.
In addition to the risks and uncertainties discussed above you can find additional information concerning risks and uncertainties that would cause actual results to differ materially from those projected or suggested in the forward-looking statements in the reports that we have filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release represent our judgment as of the date of this release and you should not unduly rely on such statements. Unless otherwise required by law, we undertake no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise after the date of this press release. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in the filing may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.
For more information, please contact: Media Relations Suzanne Beranek, APR, Beranek Communications, LLC 407-475-0763 or via email at suzanne@beranekcommunications.com Investor/Shareholder Relations Elite Financial Communications Group, LLC Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist 407-585-1080 or via email at prz@efcg.net
SOURCE PainCare Holdings, Inc.
http://www.paincareholdings.com
What happened to your sell of .19 a couple of months ago and then your sell rec of .14???
Cubist Pharmaceuticals to Announce Third Quarter 2007 Financial Results on Wednesday, October 17, 2007
9:10a ET October 3, 2007 (Business Wire)
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its third quarter 2007 financial results at 4:00 p.m. EDT on Wednesday, October 17, 2007. In connection with this announcement, Cubist will host a conference call and live audio webcast (with slides) at 5:00 p.m. EDT that same day to discuss its third quarter financial results, business activities and financial outlook.
As always, the quarterly earnings call will be available via phone and webcast. The phone call dial-in information is listed below. To access the webcast, please log on to the Cubist website at www.cubist.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
A replay of the webcast and teleconference will be available on Cubist's website beginning approximately three hours after the call. **********CONFERENCE CALL & WEBCAST INFORMATION********** Cubist will host a conference call and live audio webcast to discuss its third quarter 2007 financial results, business activities and financial outlook. WHEN: Wednesday, October 17, 2007 at 5:00 p.m. EDT LIVE DOMESTIC & CANADA CALL-IN: 877-407-0778 LIVE INTERNATIONAL CALL-IN: 201-689-8565 24-HOUR REPLAY DOMESTIC & CANADA: 877-660-6853 24-HOUR REPLAY INTERNATIONAL: 201-612-7415 REPLAY PASSCODES (BOTH REQUIRED FOR PLAYBACK): ACCOUNT #: 286 CONFERENCE ID #: 252157 CALL WILL ALSO BE BROADCAST LIVE, LISTEN ONLY, VIA THE WEB AT: www.cubist.com Replay will be available for 30 days at www.cubist.com *****************************************************************
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. The Cubist product pipeline includes pre-clinical programs that address unmet medical need in Gram-positive infections, Gram-negative infections, and CDAD (Clostridium difficile-associated diarrhea). Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.
SOURCE: Cubist Pharmaceuticals, Inc.
Cubist Pharmaceuticals, Inc. Eileen C. McIntyre, 781-860-8533 Senior Director, Corporate Communications eileen.mcintyre@cubist.com
2C was old moderator
Where is he now?
Perhaps he can be the cellmate of PV from SLJB. Can you just see them discussing the pros and cons of AURC and SLJB.
Thanks NWOL management (?), you have kept your word just as you have in all of your PR's (?). You promised a pps of above .30 by end of Sept and today it is a whopping .95!!!!! I could not have done better myself-----on 2nd thought my 3 year old grandbaby could have done better!
Beware of CWTE spam/scam today:
http://investorshub.advfn.com/boards/board.asp?board_id=7707
CWTE spam/scam today:
Sym: CWTE
Price: $.47 (UP 25% TODAY)
Today range: 0.35-1.36!!!
5 Day : $2.00
AMAZING stock!
I thought someone said the OSC is already after Parkin. Is this happening? If not, they should have been after his @@@ after the NDOL big lie.
I have received 8-10 of them and forwarded all to SEC,pinksheets,spam,etc. I also have signed up with spamcop.net, which a poster here recommended, and send all spam to them.
Looks like a 250k buy just went thru.
NanoViricides CEO to Air on Live MN1 Interview
Monday October 1, 9:16 am ET
WEST HAVEN, CT--(MARKET WIRE)--Oct 1, 2007 -- NanoViricides (OTC BB:NNVC.OB - News) announced today that Dr. Eugene Seymour, CEO of NanoViricides, will be appearing on Market News First www.mn1.com at 2:00 PM CDT on October 3, 2007. Seymour will be talking with the MN1 news team about key Company developments.
To learn more NanoViricides and how it is changing the marketplace, log on www.mn1.com on October 3, 2007 at 2:00 PM CDT.
http://www.mn1.com -- Market News First